Trastuzumab in the management of early and advanced stage breast cancer. - Wikidata - awgldk - TriplyDB

Trastuzumab in the management of early and advanced stage breast cancer.

Trastuzumab in the management of early and advanced stage breast cancer.

http://www.wikidata.org/entity/Q37290613

about

The Anti-Cancer Effect of Polyphenols against Breast Cancer and Cancer Stem Cells: Molecular Mechanisms Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine.SRSF3 and hnRNP H1 regulate a splicing hotspot of HER2 in breast cancer cells.Precision glycocalyx editing as a strategy for cancer immunotherapy.Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer.Folate Receptor-Positive Gynecological Cancer Cells: In Vitro and In Vivo Characterization.The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance.Cardiotoxicity of Anticancer Therapeutics.Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.Effectiveness of trastuzumab as adjuvant therapy in patients with early stage breast cancer: A systematic review and meta-analysis.

P2860

Q28066752-DB8F6187-D751-4E5B-AFD3-781599CEE790 Q28068290-388AEDDE-DE1C-4B3D-8C1D-7C1C31CD88CB Q33410791-39D5E9D1-8D03-4125-A989-AE800193A13F Q33823065-5D3F9240-141E-40B8-A16E-0EF490B02C42 Q36791562-16CAF4D3-B1B9-4D8F-9AA5-8E46AB69D8DE Q37264064-B942B7D7-AEBA-4DBF-98E7-18F96895FE25 Q37588298-EBE4F9A3-C861-4A55-95C6-BE1F59D3B50B Q42070603-E4A7644E-CB39-4663-B728-F075AECED08B Q42366884-4EF4A7A4-A6C5-4BC9-A2BC-2800089353FF Q47415861-08C787EC-BE8C-4058-A08B-3FC6C8A2C56B Q50326869-C11C5910-DC0F-46A0-81F2-DC8556ACD462 Q52343895-62432D92-F35D-4B12-BA04-1F24659F3F55 Q55314739-4617607E-AD60-430E-A41E-07244C9F4A67

P2860

Trastuzumab in the management of early and advanced stage breast cancer.

http://www.wikidata.org/entity/Q37290613

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Trastuzumab in the management of early and advanced stage breast cancer.

@en

Trastuzumab in the management of early and advanced stage breast cancer.

@nl

type

label

Trastuzumab in the management of early and advanced stage breast cancer.

@en

Trastuzumab in the management of early and advanced stage breast cancer.

@nl

prefLabel

Trastuzumab in the management of early and advanced stage breast cancer.

@en

Trastuzumab in the management of early and advanced stage breast cancer.

@nl

P1433

Q37290613-FAF1D6FF-69BF-458F-8A0F-DE51642EC618

P1476

Q37290613-17161D4F-A43C-4B3A-9CD3-E05227E12476

P2093

Q37290613-8ABE6E83-128F-44E5-B0CC-B9B0295FFDB1

Q37290613-9F5FFED2-E837-499C-AD46-42B4F03F00D7

Q37290613-AEFBB60E-60B5-4FB5-9E57-346058A5F5B1

P2860

Q37290613-0269251B-0DBF-4B4F-9840-AA2F8229C8DC

Q37290613-04B0E430-E982-40DB-A0EE-764A0F95EBCC

Q37290613-05091D46-B512-464C-8ABC-CF7EA4905030

Q37290613-06D9FA80-5CB3-4795-8C3B-7E110251C5EC

Q37290613-080F0A2B-0D24-49F3-BF20-F88473E4DBB6

Q37290613-0992D3A1-9B03-4E3A-937B-2D4BE7649316

Q37290613-0F1CC7D0-F710-4854-A945-FDD4E77C7AF1

Q37290613-1642FD43-393C-401F-B3F1-47B44F14EE16

Q37290613-180B3989-26AA-4650-87A6-4746EE0E69EE

Q37290613-1B56AED6-91A1-4A0A-8751-2F1250824ABF

P304

Q37290613-95A18183-55B3-4101-8C1E-4AEE27F830F4

P31

Q37290613-4CF29D9C-33CD-4993-9078-6537CD748A17

P433

Q37290613-CEEB5325-E5B8-47A2-925B-04939C3D4258

P478

Q37290613-1553EAD1-AED6-4FD6-8769-4F6A4C875674

P577

Q37290613-66DA280B-D0D8-47FA-8126-005DC2E43B78

P698

Q37290613-8F0B5130-6184-4640-B8BD-1FFED0CD2A95

P932

Q37290613-8C02519A-46FD-48D7-9149-65468CEE4B01

P1433

Biologics: Targets and Therapy

P1476

Trastuzumab in the management of early and advanced stage breast cancer

@en

P2093

Catharina Wenzel

http://www.w3.org/2001/XMLSchema#string

Guenther G Steger

http://www.w3.org/2001/XMLSchema#string

Rupert Bartsch

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Gene expression profiling predicts clinical outcome of breast cancer

A gene-expression signature as a predictor of survival in breast cancer

P304

19-31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19707345

http://www.w3.org/2001/XMLSchema#string

P932

2721347

http://www.w3.org/2001/XMLSchema#string